600572.SHG Zhejiang CONBA Pharmaceutical Co Ltd
- Market cap
- CNY 11.1B
- P/E
- 24.2x
- P/B
- 1.53x
- ROE
- 10.4%
- Dividend yield
- 3.47%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600572.SHG undervalued?
Graham number600572.SHG trades 28.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang CONBA Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang CONBA Pharmaceutical Co Ltd yet.
Zhejiang CONBA Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang CONBA Pharmaceutical Co Ltd
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nutritional supplements, hygiene products, healthy daily chemicals and food, and other self-…
Full company profileZhejiang CONBA Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang CONBA Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.02B | 5.29B | 7.02B | 6.77B | 5.91B | 6.57B | 6.00B | 6.73B | 6.52B | 6.47B | 7.11B |
| Gross Profit | 2.86B | 3.83B | 5.33B | 5.04B | 3.82B | 3.94B | 3.53B | 3.90B | 3.41B | 3.45B | 3.99B |
| Operating Income | 476M | 909M | 1.05B | -39.1M | 784M | 2.53B | 602M | 788M | 799M | 624M | 976M |
| EBITDA | 910M | 1.21B | 1.33B | 1.18B | 848M | 957M | 963M | 1.13B | 914M | 998M | 937M |
| Net Income | 441M | 711M | 815M | -346M | 453M | 2.02B | 358M | 592M | 622M | 474M | 755M |
| EPS | 0.18 | 0.28 | 0.31 | -0.13 | 0.18 | 0.78 | 0.14 | 0.23 | 0.25 | 0.19 | 0.30 |
| Balance Sheet | |||||||||||
| Total Assets | 8.50B | 9.42B | 10.7B | 9.86B | 9.28B | 10.8B | 10.9B | 11.2B | 9.90B | 9.98B | 10.5B |
| Total Liabilities | 4.01B | 3.58B | 4.92B | 4.92B | 3.93B | 3.40B | 3.61B | 3.89B | 2.99B | 2.83B | 3.09B |
| Shareholders' Equity | 4.30B | 5.73B | 5.65B | 4.66B | 5.03B | 7.06B | 6.91B | 7.04B | 6.82B | 7.05B | 7.26B |
| Cash & Short-term Investments | 1.98B | 2.31B | 1.63B | 1.70B | 1.58B | 2.49B | 2.47B | 2.57B | 1.32B | 1.67B | 832M |
| Total Debt | 1.99B | 1.60B | 2.54B | 2.68B | 2.36B | 1.49B | 1.20B | 954M | 330M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 970M | 712M | 546M | 926M | 1.25B | 890M | 1.16B | 899M | 1.01B | 943M | - |
| Capital Expenditure | 232M | 292M | 380M | 269M | 460M | 568M | 292M | 209M | 291M | 147M | 215M |
| Free Cash Flow | 738M | 420M | 166M | 657M | 789M | 322M | 864M | 689M | 722M | 795M | 879M |
| Ratios | |||||||||||
| ROE | 10.2% | 12.4% | 14.4% | -7.4% | 9.0% | 28.6% | 5.2% | 8.4% | 9.1% | 6.7% | 10.4% |
| ROA | 5.2% | 7.5% | 7.6% | -3.5% | 4.9% | 18.7% | 3.3% | 5.3% | 6.3% | 4.8% | 7.2% |
| Net Profit Margin | 7.3% | 13.4% | 11.6% | -5.1% | 7.7% | 30.7% | 6.0% | 8.8% | 9.6% | 7.3% | 10.6% |
| Debt to Equity | 0.46x | 0.28x | 0.45x | 0.58x | 0.47x | 0.21x | 0.17x | 0.14x | 0.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang CONBA Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.47%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 80.9%
- Ex-dividend date
- Jun 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 384M | 0.15 | 80.9% |
| 2024 | CNY 524M | 0.21 | 84.1% |
| 2023 | CNY 420M | 0.16 | 71.0% |
| 2022 | CNY 490M | 0.19 | 136.9% |
| 2021 | CNY 85.0M | 0.03 | 4.2% |
| 2020 | CNY 143M | 0.06 | 31.5% |
| 2019 | CNY 386M | 0.14 | - |
| 2018 | CNY 485M | 0.18 | 59.6% |
| 2017 | CNY 318M | 0.13 | 44.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on Jun 15, 2016.
Who owns Zhejiang CONBA Pharmaceutical Co Ltd
- Insiders 37.01%
- Institutions 3.68%
- Public & others 59.32%
- Shares outstanding 2.54B
- Free float 1.65B
Zhejiang CONBA Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang CONBA Pharmaceutical Co Ltd
- Ticker
- 600572.SHG
- ISIN
- CNE000001H86
- Exchange
- Shanghai Stock Exchange
- Listed since
- Apr 12, 2004
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7,826
- Fiscal year end
- December
- Address
- Binjiang Science and Technology Economic Park, Hangzhou, China, 310051
- Phone
- 86 571 8777 4811
- Website
- conbapharm.com
About Zhejiang CONBA Pharmaceutical Co Ltd
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nutritional supplements, hygiene products, healthy daily chemicals and food, and other self-care products; and processes agricultural products. In addition, it offers prescription pieces, formula granules, plant extracts, and other products. The company offers its products under Aokang, Jindi, Jinaikang, Qianliekang, Tianbaoning, Jinkang Su, Li, Zhixinyan, Kang Enbei, Baozhilin, and Yangyingtang brands. The company was formerly known as Lanxi Yunshan Pharmaceutical Factory and changed its name to Zhejiang CONBA Pharmaceutical Co.,Ltd. in October 1999. Zhejiang CONBA Pharmaceutical Co.,Ltd. was founded in 1969 and is headquartered in Hangzhou, China.
Zhejiang CONBA Pharmaceutical Co Ltd management
4- Mr. Ming ChenVP, CFO & Financial Controller · born 1977
- Mr. Jianfeng YeVP & Director · born 1974
- Mr. Zucheng JinVP & Board Secretary · born 1976
- Mr. Shishui YinVice President · born 1975